RSI at 26 on a Guillain-Barré Play, and the CEO Adds
Annexon is a clinical-stage biotech with a monoclonal antibody in Phase 3 for Guillain-Barré syndrome, and CEO Douglas Love just put $99,829 into it near the bottom of its yearly range. RSI at 26 and a stock down 48% from its high show the tape hates this one, but healthcare is one of the few sectors catching the defensive bid right now, and the sector is up 11% over three months. What makes this more than a footnote is the history: past insider buys on this name have paid off about 70% of the time, with an average 28% return over the next 90 days. The read on a clinical-stage biotech is always binary and this is only a 7% add to his stake, so size it like the science lottery ticket it is.
The Filing
| Ticker | ANNX |
| Company | Annexon, Inc. |
| Insider | Douglas Love, PRESIDENT AND CEO |
| Buy amount | $99,829 |
| Filing date | September 25, 2026 |
| Conviction | Interesting · 56/100 |
| Setup type | Contrarian Setup |
Ultimate members received this analysis in real time.